These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37415440)

  • 1. Temporal association between the age-specific incidence of Guillain-Barré syndrome and SARS-CoV-2 vaccination in Republic of Korea: a nationwide time-series correlation study.
    Lee H; Kwon D; Park S; Park SR; Chung D; Ha J
    Osong Public Health Res Perspect; 2023 Jun; 14(3):224-231. PubMed ID: 37415440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering changes in the incidence of the Guillain-Barré syndrome during the COVID-19 pandemic: a nationwide time-series correlation study.
    Lee H; Heo N; Kwon D; Ha J
    BMJ Neurol Open; 2022; 4(2):e000378. PubMed ID: 36618976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis.
    Reddy YM; Murthy JM; Osman S; Jaiswal SK; Gattu AK; Pidaparthi L; Boorgu SK; Chavan R; Ramakrishnan B; Yeduguri SR
    Clin Exp Vaccine Res; 2023 Apr; 12(2):143-155. PubMed ID: 37214140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Guillain-Barré syndrome in South Korea during the early COVID-19 pandemic.
    Choi SA; Hwang J; Lim BC; Chae SA
    Front Neurol; 2023; 14():1125455. PubMed ID: 36895908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
    Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
    Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barré syndrome?
    Zheng X; Fang Y; Song Y; Liu S; Liu K; Zhu J; Wu X
    Eur J Med Res; 2023 Feb; 28(1):98. PubMed ID: 36841799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
    Kim JE; Park J; Min YG; Hong YH; Song TJ
    J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.
    Malekpour M; Khanmohammadi S; Meybodi MJE; Shekouh D; Rahmanian MR; Kardeh S; Azarpira N
    Immun Inflamm Dis; 2023 May; 11(5):e875. PubMed ID: 37249286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N
    Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and Guillain-Barré syndrome: A single-center prospective case series with a 1-year follow-up.
    Ahmad L; Businaro P; Regalbuto S; Gastaldi M; Zardini E; Panzeri M; Vegezzi E; Fiamingo G; Colombo E; Ravaglia S
    Medicine (Baltimore); 2022 Jul; 101(30):e29704. PubMed ID: 35905215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the 'Italian factor'.
    Censi S; Bisaccia G; Gallina S; Tomassini V; Uncini A
    Eur J Neurol; 2024 Feb; 31(2):e16094. PubMed ID: 37823707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study.
    Luijten LWG; Leonhard SE; van der Eijk AA; Doets AY; Appeltshauser L; Arends S; Attarian S; Benedetti L; Briani C; Casasnovas C; Castellani F; Dardiotis E; Echaniz-Laguna A; Garssen MPJ; Harbo T; Huizinga R; Humm AM; Jellema K; van der Kooi AJ; Kuitwaard K; Kuntzer T; Kusunoki S; Lascano AM; Martinez-Hernandez E; Rinaldi S; Samijn JPA; Scheidegger O; Tsouni P; Vicino A; Visser LH; Walgaard C; Wang Y; Wirtz PW; Ripellino P; Jacobs BC;
    Brain; 2021 Dec; 144(11):3392-3404. PubMed ID: 34553216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome and COVID-19: A 1-year observational multicenter study.
    Filosto M; Cotti Piccinelli S; Gazzina S; Foresti C; Frigeni B; Servalli MC; Sessa M; Cosentino G; Marchioni E; Ravaglia S; Briani C; Castellani F; Zara G; Bianchi F; Del Carro U; Fazio R; Filippi M; Magni E; Natalini G; Palmerini F; Perotti AM; Bellomo A; Osio M; Nascimbene C; Carpo M; Rasera A; Squintani G; Doneddu PE; Bertasi V; Cotelli MS; Bertolasi L; Fabrizi GM; Ferrari S; Ranieri F; Caprioli F; Grappa E; Manganotti P; Bellavita G; Furlanis G; De Maria G; Leggio U; Poli L; Rasulo F; Latronico N; Nobile-Orazio E; Beghi E; Padovani A; Uncini A
    Eur J Neurol; 2022 Nov; 29(11):3358-3367. PubMed ID: 35837806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
    Lunn MP
    Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience.
    Caress JB; Castoro RJ; Simmons Z; Scelsa SN; Lewis RA; Ahlawat A; Narayanaswami P
    Muscle Nerve; 2020 Oct; 62(4):485-491. PubMed ID: 32678460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.